Aurobindo Pharma to invest $200 million on Capex in FY20

17 Jun 2019 Evaluate

Aurobindo Pharma is eyeing to invest up to $200 million on Capex and over five percent of sale value on Research and Development (R&D) during the current financial year. The majority of the CAPEX should be in terms of creating certain both finished dosage and API capacities.

The company had spent $225 million on capex last year and R&D expenditure was at Rs 872 crore or 4.5 percent of the revenues for the year.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1180.25 0.00 (0.00%)
14-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1700.55
Dr. Reddys Lab 1186.45
Cipla 1434.60
Zydus Lifesciences 884.00
Lupin 2195.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×